ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1516

Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors

M. Victoria Hernández1, Marina Mesquida1, Victor Llorens2, Maite Sainz de la Maza2, Ricardo Blanco3, Vanesa Calvo4, Olga Maiz5, Ana Blanco6, Ana Urruticoechea-Arana7, Juan Ramon De Dios8, Pilar Ahijado-Guzman9, Enrique Judez10, Patricia Tejón11, M Soledad Peña12, Francisca Sivera13, Alfredo Adan1 and Raimon Sanmarti14, 1Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 2Ophthalmology Department. Hospital Clínic of Barcelona, Barcelona, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology Department. Hospital Universitario Marqués de Valdecilla., Santander, Spain, 5Hospital Donostia. Spain, San Sebastian, Spain, 6Ophthalmology Department. Hospital Donostia, San Sebastian, Spain, 7Rheumatology Department. Hospital Can Misses, IBIZA, Spain, 8Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, 9Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, 10Rheumatology Department. Hospital de Albacete, Albacete, Spain, 11Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, 12Ophtalmology Department. Hospital Universitario General de Castellón, Castellon, Spain, 13Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, 14Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: certolizumab pegol, Spondylarthritis, tumor necrosis factor (TNF) and uveitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Uveitis is a common extra-articular manifestation in patients with spondyloarthritis (SpA) requiring, in most severe cases, the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi). Currently, the most frequently TNFi used are infliximab and adalimumab. However, in cases of failure or adverse events related to these drugs, other TNFi (with indication for SpA patients) such as certolizumab pegol (CZP) could be an effective option for both uveitis and SpA control, as we have previously reported (1). Our purpose is to analyze the effectiveness and safety profile of CZP in patients with SpA-associated- uveitis refractory to previous immunosuppressive or biological therapy.

Methods:

Observational, multicentric, retrospective study. Inclusion criteria were: patients with SpA and with a diagnosis of uveitis (confirmed by an Ophtalmologist) as main extra-articular SpA manifestation, refractory to previous immunosuppressive or biological agents and who received CZP for at least 6 months. Variables analyzed: age, sex, diagnosis, type of uveitis, duration since the first uveitis episode and number of eyes affected; previous treatment (NSAID, disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressive, biological therapy); outcome and time to follow-up.

Results:

Twenty-two eyes of 13 patients (10 men); age 50.4 ± 11.7 (range 29-71 years) were included in the study. Diagnosis were: ankylosing spondylitis (n=7), psoriatic arthritis (n=4), non-radiographic axial SpA (n=1) and SpA associated to inflammatory bowel disease (n=1). Type of uveitis: 14 anterior (63.6%), 6 panuveitis (27.2%), and 2 intermediate uveitis (9.1%). Mean disease duration was 161.7 ± 138.5 months (range 5-420). 84.6% patients had previously received biological therapy (53.8% > 2 biological agents). 69.2% received CZP in monotherapy and 5 patients received concomitant treatment: 4 methotrexate and 1 azathioprine. In all cases CZP was started due to inefficacy to previous treatment except for 2 cases whose primary reason was the concurrence of adverse events or intolerance. After a follow-up of 17.8 ± 9.9 months (range 6-39), 8 patients are still on CZP treatment. Thirteen eyes showed improvement of visual acuity (59.1%), 7 remained stable and 2 worsened. During the follow-up no serious adverse events were reported. Five cases withdrew CZP treatment: 2 due to worsening of articular symptoms but with no uveitis activity; 1 due to persistence of macular edema and 2 due to uveitis activity. Two patients switched to infliximab, one to golimumab, one to adalimumab and one required switch to tocilizumab due to persistence of macular edema. In all 13 patients except 2, CZP achieved a good control of SpA activity.

Conclusion:

CZP demonstrates moderate effectiveness in patients with SpA-associated-uveitis refractory to previous TNFi treatment, with a good safety profile.

References: 1. Llorenç V et al. Ocul Immunol Inflamm. 2016; 24: 167-72.


Disclosure: M. V. Hernández, None; M. Mesquida, None; V. Llorens, None; M. Sainz de la Maza, None; R. Blanco, None; V. Calvo, None; O. Maiz, None; A. Blanco, None; A. Urruticoechea-Arana, None; J. R. De Dios, None; P. Ahijado-Guzman, None; E. Judez, None; P. Tejón, None; M. S. Peña, None; F. Sivera, None; A. Adan, AbbVie, Santen and Allergan, 9; R. Sanmarti, None.

To cite this abstract in AMA style:

Hernández MV, Mesquida M, Llorens V, Sainz de la Maza M, Blanco R, Calvo V, Maiz O, Blanco A, Urruticoechea-Arana A, De Dios JR, Ahijado-Guzman P, Judez E, Tejón P, Peña MS, Sivera F, Adan A, Sanmarti R. Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/effectiveness-of-certolizumab-pegol-in-patients-with-uveitis-associated-to-spondyloarthritis-refractory-to-other-tumour-necrosis-factor-inhibitors/. Accessed July 1, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-of-certolizumab-pegol-in-patients-with-uveitis-associated-to-spondyloarthritis-refractory-to-other-tumour-necrosis-factor-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies